Skeletal Muscle Hypertrophy and Muscle Myostatin Reduction After Resistive Training in Stroke Survivors

  • Alice S. Ryan
    From the University of Maryland School of Medicine, Department of Medicine, Division of Gerontology and Geriatric Medicine (A.S.R., S.P., G.L.), and Department of Neurology (F.M.I., C.M.), Baltimore Veterans Affairs Research and Development Service, GRECC and MERCE Centers, Baltimore, MD.
  • Frederick M. Ivey
    From the University of Maryland School of Medicine, Department of Medicine, Division of Gerontology and Geriatric Medicine (A.S.R., S.P., G.L.), and Department of Neurology (F.M.I., C.M.), Baltimore Veterans Affairs Research and Development Service, GRECC and MERCE Centers, Baltimore, MD.
  • Steven Prior
    From the University of Maryland School of Medicine, Department of Medicine, Division of Gerontology and Geriatric Medicine (A.S.R., S.P., G.L.), and Department of Neurology (F.M.I., C.M.), Baltimore Veterans Affairs Research and Development Service, GRECC and MERCE Centers, Baltimore, MD.
  • Guoyan Li
    From the University of Maryland School of Medicine, Department of Medicine, Division of Gerontology and Geriatric Medicine (A.S.R., S.P., G.L.), and Department of Neurology (F.M.I., C.M.), Baltimore Veterans Affairs Research and Development Service, GRECC and MERCE Centers, Baltimore, MD.
  • Charlene Hafer-Macko
    From the University of Maryland School of Medicine, Department of Medicine, Division of Gerontology and Geriatric Medicine (A.S.R., S.P., G.L.), and Department of Neurology (F.M.I., C.M.), Baltimore Veterans Affairs Research and Development Service, GRECC and MERCE Centers, Baltimore, MD.

抄録

<jats:sec> <jats:title>Background and Purpose—</jats:title> <jats:p>Stroke survivors experience disproportionate muscle atrophy and other detrimental tissue composition changes on the paretic side. The purpose was to determine whether myostatin levels are higher in paretic vs nonparetic muscle and the effects of resistive training (RT) on paretic and nonparetic mid-thigh muscle composition and myostatin mRNA expression in stroke survivors.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods—</jats:title> <jats:p>Fifteen stroke survivors (50–76 years) underwent bilateral multi-slice thigh CT scanning from the knee to the hip, bilateral vastus lateralis skeletal muscle tissue biopsies, a total body scan by dual-energy X-ray absorptiometry, and 1-repetition maximum strength test before and after a 12-week, (3 times/week) RT intervention.</jats:p> </jats:sec> <jats:sec> <jats:title>Results—</jats:title> <jats:p> Total body fat mass and fat-free mass did not change. Bilateral leg press and leg extension 1-repetition maximum strength increased 31% to 56% with RT ( <jats:italic>P</jats:italic> <0.001). Paretic and nonparetic muscle area of the mid-thigh increased 13% ( <jats:italic>P</jats:italic> <0.01) and 9% ( <jats:italic>P</jats:italic> <0.05), respectively, after RT. Muscle attenuation of the mid-thigh increased 15% and 8% (both <jats:italic>P</jats:italic> <0.01) in the paretic and nonparetic thigh, respectively, representing reduced intramuscular fat. Muscle volume increased 14% ( <jats:italic>P</jats:italic> <0.001) in the paretic thigh and 16% ( <jats:italic>P</jats:italic> <0.05) in the nonparetic thigh after RT. Myostatin mRNA expression levels were 40% higher in the paretic than nonparetic muscle ( <jats:italic>P</jats:italic> =0.001) at baseline and decreased 49% in the paretic muscle ( <jats:italic>P</jats:italic> <0.005) and 27% in the nonparetic muscle ( <jats:italic>P</jats:italic> =0.06) after RT. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>Progressive RT stimulates significant muscle hypertrophy and intramuscular fat reductions in disabled stroke survivors. The increased myostatin mRNA in the paretic thigh and reduction with RT imply an important regulatory role for myostatin after stroke.</jats:p> </jats:sec>

収録刊行物

  • Stroke

    Stroke 42 (2), 416-420, 2011-02

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (13)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ